Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70160 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Stefan Markus Dendorfer und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: Daunorubicin, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität Dresden.
Abstract (Originalsprache)
Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the associated risk for cardiotoxicity remain under debate. The DaunoDouble trial compared daunorubicin at 60 (Dauno60) versus 90 mg/m 2 (Dauno90) in combination with cytarabine (100 mg/m 2 for 7 days) in newly diagnosed AML patients aged 18–65 years. Cardiac function was assessed by left ventricular ejection fraction (LVEF) and cardiac biomarkers (high‐sensitivity troponin T [hsTnT], NT‐proBNP) before treatment and on Day 15 in 317 randomized patients. Median LVEF declined significantly from 65% [IQR 60%–68.5%] to 61% [IQR 58%–67.8%] across all patients ( p < 0.01), without significant differences between treatment arms. NT‐proBNP levels measured after induction therapy correlated negatively with LVEF at the same time point ( ρ = −0.24, p = 0.02), but did not change significantly during induction—neither between Day 1 and 15 nor between treatment arms. HsTnT levels increased significantly from 5 [IQR 4–8] to 8 ng/L [IQR 6–14] across all patients ( p < 0.01), with higher post‐induction values in the Dauno90 group (9.5 ng/L [IQR 7–14]) compared to Dauno60 (7 ng/L [IQR 5–14]; p < 0.01). In exploratory subgroup analyses, post‐induction hsTnT levels were also significantly higher in patients with obesity and arterial hypertension. These findings provide evidence of a dose‐dependent cardiotoxic effect of daunorubicin, already apparent at standard induction doses, and underscore the importance of early cardiac monitoring. Long‐term follow‐up will be essential to determine the clinical significance of these early changes. Trial Registration: ClinicalTrials.gov identifier: NCT02140242
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
- Cognium GmbH, Bern, Switzerland.
- Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany.
- Department of Medicine A, University Hospital Münster, Münster, Germany.
- Department of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany.
- Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Stefan Markus Dendorfer, Maher Hanoun, Sabine Kayser, Jiri Mayer
Förderung
- Technische Universität Dresden
Zitieren
APA
Dendorfer, S. M., Schmidt-Brücken, K., Kramer, M., Steffen, B., Schliemann, C., Mikesch, J. H., Alakel, N., Herbst, R., Hänel, M., Hanoun, M., Kaufmann, M., Weinbergerova, B., Schäfer-Eckart, K., Sauer, T., Neubauer, A., Burchert, A., Baldus, C. D., Mertová, J., Jost, E., …, & Röllig, C. (2026). Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy. American Journal of Hematology. https://doi.org/10.1002/ajh.70160
Vancouver
Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH, et al. Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy. American Journal of Hematology. 2026. doi:10.1002/ajh.70160
BibTeX
@article{Dendorfer2026,
author = {Dendorfer, Stefan Markus and Schmidt-Brücken, Katharina and Kramer, Michael and Steffen, Björn and Schliemann, Christoph and Mikesch, Jan-Henrik and Alakel, Nael and Herbst, Regina and Hänel, Mathias and Hanoun, Maher and Kaufmann, Martin and Weinbergerova, Barbora and Schäfer-Eckart, Kerstin and Sauer, Tim and Neubauer, Andreas and Burchert, Andreas and Baldus, Claudia D and Mertová, Jolana and Jost, Edgar and Niemann, Dirk and Novák, Jan and Krause, Stefan W and Scholl, Sebastian and Hochhaus, Andreas and Held, Gerhard and Szotkowski, Tomáš and Rank, Andreas and Schmid, Christoph and Fransecky, Lars and Kayser, Sabine and Schaich, Markus and Fiebig, Frank and Haake, Annett and Schetelig, Johannes and Middeke, Jan Moritz and Stölzel, Friedrich and Platzbecker, Uwe and Thiede, Christian and Müller-Tidow, Carsten and Berdel, Wolfgang E and Ehninger, Gerhard and Mayer, Jiri and Serve, Hubert and Bornhäuser, Martin and Röllig, Christoph},
title = {Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70160}
}
EUVIMED